Next Article in Journal
Efficacy and Safety of Levofloxacin Treatment of Community—Acquired Pneumonia in Hospitalized Patients
Previous Article in Journal
The Influence of 3 Weeks Therapy with Continuous Positive Airway Pressure on Serum Leptin and Homocysteine Concentration in Patients with Obstructive Sleep Apnea Syndrom
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bronchial Obstruction Reversibility Test in the Assessment of COPD Severity—Controversies

by
Marta Maskey-Warzęchowska
1,*,
Monika Pankowska
2 and
Ryszarda Chazan
1
1
Katedra i Klinika Ch. Wewnętrznych, Pneumonologii i Alergologii AM w Warszawie, Warsaw, Poland
2
Studenckie Koło Naukowe przy w/w Katedrze, Kraków, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2006, 74(1), 68-71; https://doi.org/10.5603/ARM.28073
Submission received: 1 March 2006 / Revised: 1 March 2006 / Accepted: 1 March 2006 / Published: 1 March 2006

Abstract

The GOLD and ERS/ATS guidelines recommend the post-bronchodilator FEV1 (% predicted) to define the severity of chronic obstructive pulmonary disease (COPD). Yet in various publications authors analyze the pre-bronchodilator value or do not clearly state which value was used when the bronchial reversibility test was performed. The guidelines established by the Polish Respiratory Society (PRS) do not specify if performing the reversibility test is necessary to estimate the COPD severity and suggest a reversibility test evaluation which differs from that in the ERS/ ATS and GOLD recommendations. Aim: to assess the changes in the degree of severity of COPD in the classification based upon the pre- and post-bronchodilator FEV1 and to compare the interpretation of the reversibility test as suggested by GOLD and ATS/ ERS and the PRS. Methods: 145 COPD patients (67F, 78M, mean age 67.5 ± 8.9 yrs) with a negative bronchial obstruction reversibility test (salbutamol 400 μg) were enrolled to the study. For each patient the degree of COPD severity using the pre- and postbronchodilator FEV1 was established. The pre- and post-bronchodilator classifications were compared. Differences in the interpretation of the reversibility test according to the GOLD and ATS/ ERS and the Polish guidelines were analyzed. Results: In 22 subjects (15.2%) the degree of disease severity changed after salbutamol. The changes were most frequent in the group of severe and very severe COPD (77.3% of changes). In 1 patient (0.7%) post-bronchodilator severity was greater than before salbutamol intake. In 7 patients (4.8%) the post-bronchodilator FEV1/FVC exceeded 70%, thus excluding the diagnosis of COPD. Of all the 145 negative (according to the ATS/ ERS and GOLD criteria) reversibility tests in 24 cases (16.6%) the test was positive when the criteria recommended by PRS were applied. Conclusions: the bronchial obstruction reversibility test is essential in the diagnosis and assessment of severity of COPD. Despite poor obstruction reversibility in this disease the use of pre-bronchodilator FEV1 in the assessment of COPD severity may be misleading and is an obstacle in the comparative analysis of studies in the domain of this disease. Differences in the guidelines for the management of COPD may also hinder comparative studies and influence epidemiologic data.
Keywords: COPD; reversibility test; GOLD; Polish guidelines COPD; reversibility test; GOLD; Polish guidelines

Share and Cite

MDPI and ACS Style

Maskey-Warzęchowska, M.; Pankowska, M.; Chazan, R. Bronchial Obstruction Reversibility Test in the Assessment of COPD Severity—Controversies. Adv. Respir. Med. 2006, 74, 68-71. https://doi.org/10.5603/ARM.28073

AMA Style

Maskey-Warzęchowska M, Pankowska M, Chazan R. Bronchial Obstruction Reversibility Test in the Assessment of COPD Severity—Controversies. Advances in Respiratory Medicine. 2006; 74(1):68-71. https://doi.org/10.5603/ARM.28073

Chicago/Turabian Style

Maskey-Warzęchowska, Marta, Monika Pankowska, and Ryszarda Chazan. 2006. "Bronchial Obstruction Reversibility Test in the Assessment of COPD Severity—Controversies" Advances in Respiratory Medicine 74, no. 1: 68-71. https://doi.org/10.5603/ARM.28073

APA Style

Maskey-Warzęchowska, M., Pankowska, M., & Chazan, R. (2006). Bronchial Obstruction Reversibility Test in the Assessment of COPD Severity—Controversies. Advances in Respiratory Medicine, 74(1), 68-71. https://doi.org/10.5603/ARM.28073

Article Metrics

Back to TopTop